While I’m sure die-hards will claim that Lexicon Pharmaceutical’s (LXRX) sotagliflozin still has a future, the company’s recent announcement that it would shut down the SCORED and SOLOIST long-term studies and indefinitely postpone an NDA filing due to an inability to find a partner, after getting its second appeal to the FDA on the Type 1 indication rejected, essentially brings that program to a close.
Theoretically Lexicon could still find a partner for this drug, but the reality is that it’s done as a meaningful contributor to the story. Still, the company’s